Hybrigenics - Leukaemia pipeline advances with new data
Hybrigenics has published data from a Phase II study in chronic myeloid leukaemia (CML). After one year of treatment, 40% of patients showed...
79 Views
Hybrigenics - Inecalcitol advancing towards data
Hybrigenics’ main value driver is inecalcitol. A Phase II study in chronic myeloid leukaemia (CML) is on track to complete in H218. Interim...
71 Views
Hybrigenics - H117 results released, business on track
Hybrigenics has reported H117 financial results which have been restated to reflect the sale of the proteomics division. Hybrigenics continues to...
87 Views
Fresh funds to expand clinical studies and R&D
Hybrigenics has raised €6.8m in gross proceeds through preferential subscription rights with new and existing investors. We believe the proceeds...
91 Views
Inecalcitol shows promise in CML, R&D refocus
Hybrigenics’ main focus is the development of inecalcitol as a niche treatment for leukaemia. In February it presented encouraging initial results...
83 Views
No more insights